

**IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE**

---

In re Entresto (Sacubitril/Valsartan) Patent  
Litigation

---

NOVARTIS PHARMACEUTICALS  
CORPORATION,

Plaintiff,

v.

MSN PHARMACEUTICALS INC.,  
MSN LABORATORIES PRIVATE  
LIMITED, MSN LIFE SCIENCES  
PRIVATE LIMITED, GERBERA  
THERAPEUTICS, INC., NANJING  
NORATECH PHARMACEUTICAL CO.,  
LIMITED,

Defendants.

---

NOVARTIS PHARMACEUTICALS  
CORPORATION,

Plaintiff,

v.

GERBERA THERAPEUTICS, INC.,  
NANJING NORATECH  
PHARMACEUTICAL CO., LIMITED,

Defendants.

---

) C.A. No. 20-2930-RGA

) C.A. No. 22-1395-RGA

) C.A. No. 23-401-RGA

**STIPULATION AND ORDER REGARDING SUBMISSION OF  
ADMITTED EXHIBITS CITED IN POST-TRIAL BRIEFING**

**WHEREAS** on December 18, 2024, the Court entered a Stipulation and Order setting forth a post-trial briefing schedule in the above-referenced actions involving Defendants MSN Pharmaceuticals Inc., MSN Laboratories Private Limited, and MSN Life Sciences Private Limited (collectively, “MSN”) and Gerbera Therapeutics, Inc., Nanjing Noratech Pharmaceutical Co., Limited (collectively, “Noratech”), and Plaintiff Novartis Pharmaceuticals Corporation (“Novartis”) (D.I. 1695 in C.A. No. 20-2930; D.I. 438 in 22-1395; D.I. 144 in 23-401);

**WHEREAS** on January 22, 2025, the Court entered a Stipulation and Order setting forth an extended post-trial briefing schedule in the above-referenced actions (D.I. 1750 in C.A. No. 20-2930; D.I. 456 in 22-1395; D.I. 163 in 23-401);

**IT IS HEREBY STIPULATED AND AGREED** by MSN, Noratech, and Novartis, and subject to the approval of the Court, that the deadline for Novartis and Defendants to submit copies of the admitted trial exhibits to the Court via USB drive shall be extended from February 7, 2025 to February 19, 2025.

Consistent with the Court’s instruction at trial, only admitted exhibits cited in the parties’ post-trial briefs will be included on the USB drive. Novartis will handle submission of all admitted exhibits.

DATED: January 28, 2025

MCCARTER & ENGLISH, LLP

/s/ Alexandra M. Joyce

Daniel M. Silver (#4758)  
Alexandra M. Joyce (#6423)  
Renaissance Centre  
405 N. King Street, 8th Floor  
Wilmington, Delaware 19801  
(302) 984-6300  
dsilver@mccarter.com  
ajoyce@mccarter.com

HEYMAN ENERIO GATTUSO & HIRZEL LLP

/s/ Dominick T. Gattuso

Dominick T. Gattuso (#3630)  
Denise Seastone Kraft (#2778)  
300 Delaware Avenue, Suite 200  
Wilmington, DE 19801  
(302) 472-7311  
dgattuso@hegh.law

Nicholas N. Kallas  
Christina Schwarz  
Jared L. Stringham  
VENABLE LLP  
151 W. 42<sup>nd</sup> St.  
New York, New York 10036  
(212) 307-5500  
nkallas@venable.com  
cschwarz@venable.com  
jlstringham@venable.com

*Attorneys for Plaintiff Novartis  
Pharmaceuticals Corporation*

Don J. Mizerk  
Matthew M. Kamps  
HUSCH BLACKWELL LLP  
120 South Riverside Plaza, Suite 2200  
Chicago, IL 60606  
don.mizerk@huschblackwell.com  
matt.kamps@huschblackwell.com

Thomas P. Heneghan  
HUSCH BLACKWELL LLP  
33 East Main Street, Suite 300  
Madison, WI 53703  
tom.heneghan@huschblackwell.com

*Attorneys for Defendants Gerbera  
Therapeutics, Inc. and Nanjing Noratech  
Pharmaceutical Co., Ltd.*

STAMOULIS & WEINBLATT LLC

/s/ Richard C. Weinblatt  
Stamatios Stamoulis (#4606)  
Richard C. Weinblatt (#5080)  
800 N. West Street, Third Floor  
Wilmington, DE 19801  
stamoulis@swdelaw.com  
weinblatt@swdelaw.com

Ronald M. Daignault  
Richard Juang  
Elizabeth Bernard  
DAIGNAULT IYER LLP  
8229 Boone Boulevard - Suite 450  
Vienna, VA 22182  
rdaignault@daignaultiyer.com  
rjuang@daignaultiyer.com  
ebernard@daignaultiyer.com

*Attorneys for Defendants MSN  
Pharmaceuticals Inc., MSN Laboratories  
Private Limited, and MSN Life Sciences  
Private Limited*

SO ORDERED this 29 day of January, 2025.

/s/ Richard G. Andrews

UNITED STATES DISTRICT JUDGE